FRONT PHARMACOL 潤(rùn)色咨詢

Frontiers in Pharmacology

出版年份:暫無(wú)數(shù)據(jù) 年文章數(shù):13176 投稿命中率: 開(kāi)通期刊會(huì)員,數(shù)據(jù)隨心看

出版周期:Irregular 自引率:6.3% 審稿周期: 開(kāi)通期刊會(huì)員,數(shù)據(jù)隨心看

前往期刊查詢

投稿信息

投稿信息
審稿費(fèi)用
2950.0元/篇 (網(wǎng)友貢獻(xiàn),非官方數(shù)據(jù))
版面費(fèi)用
2871.43元/篇 (網(wǎng)友貢獻(xiàn),非官方數(shù)據(jù))
中國(guó)人發(fā)表比例
2023年中國(guó)人文章占該期刊總數(shù)量暫無(wú)數(shù)據(jù) (2022年為100.00%)
自引率
6.3 %
年文章數(shù)
13176
期刊官網(wǎng)
點(diǎn)擊查看 (點(diǎn)擊次數(shù):35205)
投稿鏈接
點(diǎn)擊查看 (點(diǎn)擊次數(shù):18145次)
作者需知
點(diǎn)擊查看 (點(diǎn)擊次數(shù):7516次)
期刊簡(jiǎn)介
稿件收錄要求

Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.

Pharmacology is a medical science, as was recalled in the anniversary address for the 50th Spring Meeting in Mainz of the German Pharmacological Society in March 2009. This science, of the effect of medicinal bodies, gives us the handle to clarify the fundamental processes of life. It is also the science studying the interactions between chemicals and living beings directed to prevent, ameliorate or cure the deleterious consequences of their diseases, thereby providing medicine with weapons against diseases. Those major targets offer the opportunity to segment the field not only in studies considering pure basic topics but also by integrating basic and clinical science. This journal's editorial policy aims at identifying the most productive research projects through an evaluation by the scientific community and emphasizing proper use of translational science at both preclinical and clinical levels. Editors encourage collaboration between clinicians and basic scientists and welcome papers issued from a collaborative strategy between the academic and the private industrial sectors that could assist in the reversal of the current decline in the production of original medicines.